While several HDAC inhibitors have been tested in combination with ICIs, such as anti-PD-1 and anti-CTLA4 therapy against multiple advanced-stage solid tumors, to the best of our knowledge, the effects of HDAC4 inhibitors with ICIs have not been reported, particularly in melanoma patients. The gene discussed is HDAC4; the disease is melanoma.